Starpharma Holdings Limited
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and VivaGel. Starpharma has developed VIRALEZE, an antiviral nasal spray for COVID-19, which is complementary to vaccines and other preventative measures such as distancing and PPE. VIRALEZE is registered for sale in the UK/Europe and available in the UK through LloydsPharmacy. SPL7013 is utilised in approved products - the VivaGel condom and VivaGel BV. VivaGel BV has been licensed in >160 countries, is approved in >40 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
About Us
As a leading company in dendrimer-based drug delivery, Starpharma’s proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma’s partnered DEP® programs have the potential to generate significant future milestones and royalties.
Founded in 1996, Starpharma listed on the Australian Securities Exchange in 2000 (ASX: SPL). Starpharma securities also trade in the US under the American Depository Receipts (ADR) program, and are listed on the OCTQX platform (OTCQX:SPHRY). OTCQX is the premium tier of the US Over-the-Counter (OTC) marketplace, providing non-US companies with a visible cross-listing to access US investors, without the duplicative regulatory costs required of listing on a traditional US exchange.